Australian Public Assessment Report for Idelalisib

Information on PJP prophylaxis, CMV monitoring, dates of and lines of previous treatment, any SAEs, and any grade 2 infectious complications should be included in the dataset. The committee encouraged the use of an established lymphoma registry and for the sponsor to work cooperatively with the data custodians of extant registries. ................
................